Source link : https://newshealth.biz/health-news/abemaciclib-poised-to-be-new-standard-of-care-in-aggressive-liposarcoma/
CHICAGO — Treatment with the CDK4/6 inhibitor abemaciclib (Verzenio) offered a dramatic survival uptick in a highly aggressive soft-tissue cancer that rarely responds to chemotherapy, according to the SARC041 trial. Patients (n=108) in the phase IIII study had recurrent or metastatic dedifferentiated liposarcoma (DDLS) that had been treated with any number of prior lines of […]
The post Abemaciclib Poised to Be New Standard of Care in Aggressive Liposarcoma first appeared on News Health.
—-
Author : News Health
Publish date : 2026-05-31 18:56:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8